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Abstract - Antioxidant enzyme activities: superoxide dismutases (CuZn SOD and Mn SOD), catalase (CAT),
glutathione peroxidase (GSH-Px), glutathione-S-transferase (GST) and glutathione reductase (GR) were
determined in different brain regions: striatum, hippocampus, hypothalamus with thalamus, as well as in the rest of
the brain of rats treated subchronically with L-deprenyl, after a single dose of reserpine and in animals subchronically
treated with L-deprenyl and then with reserpine. Our results show that reserpine (p <0.02), aswell as, the combination
of deprenyl+ reserpine (p<O.01) induced a significant decrease in CAT activity in the rest of the brain and a
significant decrease in GSH-Px activity in the hypothalamus with thalamus (p<0.05). Deprenyl expressed no
significant effect on antioxidant enzyme activities in the examined brain regions. In experimental group treated with
deprenyl and then with reserpine a significant decrease of CuZn SOD activity (p<0.05) in the hippocampus, Mn
SOD activity (p<0.05) in the striatum and an increase of CnZn SOD activity (p<O.Ol) in the rest of the brain were
observed. Our results support the opinion that depletion of neuronal catecholamine pool (due to the treatment with
reserpine) has a direct influence on antioxidant enzyme activities, while deprenyl probably exerts its effects through
interaction with some trophic factors.
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INTRODUCTION
Investigations of monoamine oxidase B (MAO-B)
selective inhibitor L-deprenyl, applied in the treatment
of Parkinson's disease demonstrated its direct effects
on the activity of antioxidant enzymes in some brain
regions (Ca rrill 0 et aL 1994). It was also shown, that
deprenyl treatment leads to an increase of SOD and
CAT activities in the striatum (Carrillo et al. 1991,
1992). However, the mechanism of such an effect is still
unknown. L-deprenyl (Selegiline, Elpedryl, Movergan,
Novamex, Jumex and Juprenil) is N-methyl-N-propar-
gyl-ethylammonium chloride (Kn 0 11 et al. 1965). It is
used as antidepressive drug in the treatment of various
diseases (Knoll 1993). Increased intraneural dopa-
mine (DA) concentration after deprenyl treatment is
completely due to the inhibition of monoamine oxida-
se-catalyzed DA oxidation.
Reserpine represents an alkaloid of the plantRa-
uwolfiaserpentina. This alkaloid depletes biogenic ami-
nes (catecholamines, 5-hydroxytryptamine) both in the
central nervous system and in the peripheral adrenergic
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nervoes (L 0 r e n c - K 0 c i et al. 1995). It is common-
ly used for the induction of Parkinson's disease sy-
mptoms in laboratory animals (W olfarth et al. 1992;
Ossowska 1994) and these symptoms could be the
consequence of striatal DA depletion and an increased
DAoxidationbyMAO (Klockgether and Turski
1990).
Dopamine represents a catecholaminergic neuro-
transmitter. Its catabolism via MAO may be a potential
biological stressor (So u tho rn and Powis 1988). Pro-
duced hydrogen peroxide (H202) can damage proteins
directly through the oxidation of sulfhydryl groups or
indirectly by producing free radicals such as superoxide
anion radical and hydroxyl radical (H all iwell 1995).
Similar to other catecholamines, dopamine may be
oxidized autocatalytically producing reactive oxygen
species (ROS). Activity of antioxidant enzymes may be
affected by reactive oxygen species and their effect
(increase or decrease) depends of ROS generation.
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Deprenyl and reserpine express an opposite effect
on brain catecholamine metabolism and the action of
their combinations was rarely examined. In the present
study we decided to study the effects of deprenyl, reser-
pine and their combination on antioxidant enzyme ac-
tivities in the rat brain.
MATERIALS AND METHODS
Male Wistar rats 3.5 months old and weighing
300-350 g were used. They were kept in large open
colony cages under controlled conditions of illumina-
tion (light on: 5 a.m.-5 p.m.) and temperature (23 ±
2°C), and were allowed free access to water and food.
Animals were divided into four groups. Control
group (C) consisted of 8 animals.
In group D, (deprenyl) 8 animals were treated
intragastrally (i.g.)for seven days with L-deprenyl ("Ju-
prenil", "Zorka Pharma"-Sabac; 10 mgjkg body mass)
and on day eight received physiological saline i.g.
In group R (reserpine), 8 animals were treated for
seven days with physiological saline i.g.and on the eight
day were i.p. injected with reserpine ("Serpasil" CIBA;
5 mg/kgbody mass).
Group D + R (deprenyl + reserpine) consisted of
8 animals treated for seven days with L-deprenyl (10
mg/kgbody mass, i.g.) and on day eighth with 5 mglkg
body mass reserpine i.p.
On day 9th of the experiment all animals were
decapitated always between 8 and 10 a.m. to avoid any
possible rhythmic variations in the antioxidant level.
Fresh brains were dissected out within 3 min. Brain
regions such as striatum (caudate nucleus, nucleus pu-
tamen, substantia nigra and globus pallidum), hippoca-
mpus, hypothalamus with thalamus and the rest of the
brain were obtained by dissection on an ice cold plate
(Glowinski and Iversen 1966). Homogenization
was performed with a Janke and Kunkel (Staufen, Ger-
many) Ka-Werk Ultra-Turrax homogenizer at 0-4 °Cin
0.25 M sucrose, 1 mM EDTA and 0.05 M Tris.HCl
solution, pH 7.4 (Rossi et al. 1987; De Waziers
and Al brech t, 1987). Brain regions (100 mgoftissue
in 2 mL buffer) and the rest of the brain (100 mg of the
tissue in 1 mL buffer) were homogenized and then
sonicated for 30 sec with 10 kHz on ice to release
enzymes from subcellular particles (T'a k a d a et ai.
1982).The sonicates were centrifuged (90 min, 85 OOOg,
4°C) and the supernatants used for determination of
antioxidant enzyme activities and total protein content.
All chemicals were Sigma (St. Louis, MO.,
U.S.A.) products.
Total SOD activity was determined by the epine-
phrine method (Misra and Fridovich 1972). This
method is based on the capacity of SOD to inhibit
autooxidation of adrenaline to adrenochrome. One
unit of SOD activity was defined as the amount of
protein causing 50% inhibition of the autooxidation of
adrenaline at 26°C (P e t r 0 vic et al. 1982) in the
volume of 3.2 mL. Reaction mixture contained 3x10·4
M adrenaline, lxlO.4 M EDTA and 0.05 M NazC03,
pH 10.2. For determination of Mn SOD activity, the
assay was performed after preincubation with 8 mM
KCN. After the incubation (20 min) at room tempera-
ture, Mn SOD was determined in the same reaction
mixture as total SOD with final concentration of 4 mM
KCN. The CuZn SOD activity was calculated as the
difference between total SOD and Mn SOD activities.
CAT activity was assayed as suggested by Be utI e r
(1982) and the activity expressed as (mol HzOz/rnin/mg
protein. The method is based on the rate of HzOz
degradation by the action of CAT contained in the
examined sample followed spectrophotometrically at
230 nm in 5 mM EDTA,Tris-HCl solution, pH 8.0.
GSH-Px activity was measured using t-butyl hydro-
peroxide as a substrate (P a g l i a and Val e n tin e
1967 as modified by Tam u r a et al. 1982) and the
activity was expressed as nmol of NADPH oxidize-
d/min/mg protein. For the determination of GST ac-
tivity, 1-chloro-2,4-dinitro benzene (CDNB) was used
as a substrate (Habig et al. 1974) and the activity was
expressed as nmol GSH used/min/mg protein. GR ac-
tivity was assayed as suggested by G 1at z Ie et al.
(1974) and expressed as nmol NADPH oxidized/
/min/mg protein.
Protein content was determined by the method of
Lowry et ai. (1951) using bovine serum albumin as a
reference.
Statistical analysis of the results was based on the
Student's t test, considering the significance at a level
ofp<0.05 (Hoel 1966).
RESULTS
As shown in Fig.I, CuZn SOD activity in the rest
of the brain of animals from the group treated with
deprenyl and then with reserpine was significantly in-
creased as compared to the controls (p<O.Ol). Also,
CuZn SOD activityin the hippocampus was significant-
ly lower in D+R group (p<0.005) in comparison with
the group treated only with deprenyl.
Activity of Mn SOD (Fig.2.) in the striatum of
animals from the group treated with deprenyl and then
with reserpine was markedly lower than in the group
treated only with deprenyl (p < 0.05).
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Fig.l. Activityof copper zinc superoxide dismutase (CuZn SOD)
in the rest of the brain, striatum, hippocampus and hypotha-
lamus with thalamus in: controls-(C), deprenyl-(D), reserpine-
(R) and D+R- treated animals. The activity is expressed in
Units/mg protein. The values are means ± SE from 8 animals.
Catalase (CAT) activity (Fig.3.) in the rest of the
brain was significantly lower in both experimental
group treated with reserpine (p < 0.02) and in the group
D+R in comparison with control animals (p<O.Ol).
The highest activity of CAT was found in the striatum
of rats from the group D + R in comparison with the
controls, as well as, in the group treated with reserpine,
with statistical significance of p < 0.05.
In Table 1. the data on glutathione peroxidase
(OSH-Px) activity are listed. OSH-Px activity was sig-
nificantly lower in the hypothalamus with thalamus of
Rand D+ R rats in comparison with control animals
(p<0.05). In other examined brain regions no statistical
differences were found in relation to the activity of this
enzyme.
Tahle 1. Glutathione peroxidase (GSH-Px) activity in Units/nIg
protein in: eontrols - (C), deprenyl- (0), reserpine - (R) and 0+R-
treated animals, in the rest of the hrain, striatum, hippocampus and
hypothalamus with thalamus. The values are means ± SE from 8
animals. * C : R, p < 0.05 and *C : O+R, I' < 0.05.
aSH-Px Controls Deprenyl Reserpine D+RU/mg protein (C) (D) (R)
Rest of the brain 26.74 ± 2.06 23.35 ± 1.44 22.26 ± 2.33 23.02 ± 1.25(5.44) (3.82) (5.68) (2.29)
Straitum 11.24 ± 2.33 16.38 ± 4.42 9.95 ± 3.36 11.67:t 2.57(4.03) (7.65) (5.82) (4.44)
Hippocamus 10.47 ± 1.45 7.82 ± 1.51 9.52 ± 3.02 9.15 ± 1.20(2.51) (2.61) (5.24) (2.08)
Hupoth. + Th. 8.45 ± 2.62 8.53 ± 1.40 3,87 ± 1.43'" 3.08 ± 0,92'(4.54) (2.43) (2.49) (1.30)
D Controls (C)
D Oeprenyl (0)
D Reserpine (R)
RO+R
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Fig.2. Manganese superoxide dismutase (Mn SOD) activity
(Units/mg protein; means ± SE from 8 animals). The same brain
regions and experimental groups were examined as in Fig.I.
Table 2. summarizes glutathione-S-transferase
(OST) activity. No changes of OST activity in any ex-
perimental group and any brain region were detected.
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Tahle 2. Activity of glutathione-S-transferase (GST), in Units/mg
protein (means ± SE from 8 animals). The same hrain regions and
groups were examirierl as in Tahle 1.
aSH-Px Controls Deprenyl Reserpine D+RU/mgprotein (C) (D) (R)
Rest of the brain 163.03 ± 8.85 160.45 ± 6.72 147.71 ± 14.05 149.38 ± 19.08(23.37) (17.74) (34.28) (50.37)
Straitum 89.68 ± 19.32 142.74 ± 49.99 97.01 ± 21.62 125.40 ± 29.63(33.45) (86.59) (37.45) (51.32)
Hippocamus 87.44 ±30.94 92.00 ± 21.92 123.93 ± 12.98 109.78 ± 25.59(53.59) (37.96) (22.48) (44.33)
Hupoth. + Th, 126.35 ±37.04 119.78 ± 26.12 109.61 ± 28.71 91.01 ± 24.47(64.15) (45.25) (49.71) (42.39)
Fig.3. Activity of catalase (CAT), in Units/mg protein (means ±
SE from 8 animals). The same brain regions and groups were
examined as in the preceding Figs.
Table 3. outlines the data on glutathione reduc-
tase (OR) activity. No statistical differences were found
in any examined brain region.
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Table 3. Glutathione reductase (GR) activity (Units/mg protein;
means ± SE from 8 animals}, The same hrain regioll8 and ex-
perimental group8 were examined as ill the pr-eceding Tables,
OR Controls Deprenyl Reserpine D+RU/mgprotein (C) (D) (R)
53.67 't 6.07 50.03", 2.44 45.35 i 5.37 50.59 i 2.64Rest of the brain (6.43) (13.10) (6.98)(16.03)
126.62 r 57.32 116.66 i 32.12 61.03 i 23.78 69.71 i 11.85Straitum (99.25) (55.65) (41.19) (20.52)
91.68 ± 26.17 76.01.!: 21.41 80.59 ± 8.55 88.76 i 23.88Hippocamus (45.34) (37.09) (14.18) (41.37)
97.00 i 38.77 66.06 i 16.63 99.46 ± 20.02 134.54 i 51.98Hupoth. + Th. (67.16) (28.80) (34.68) (90.03)
DISCUSSION
Effect of combined deprenyl+reserpine treatme-
nt on CuZn SOD activity is opposite in the rest of the
brain (increase) in comparison with that in the hip-
pocampus (decrease). Opposite effect of deprenyl on
CuZn SOD activity in the brain and brain regions has
also been recorded by other authors (Ki tan i et al.
1994). These authors postulated that deprenyl effects
on CuZn SOD activity were due to an activation on
some trophic factors which were selectively regionally
distributed and not to inhibition of MAO B activity
(Ki t ani et al. 1994). We have not recorded the chan-
ges in CuZn SOD activity in hippocampus of rats trea-
ted with deprenyl and this result is in accordance with
the data of Knoll (1988) and Carrillo etal. (1991).
In contrast, in the striatum not only increased CuZn
SOD activity, but also CAT activity (but not GSH-Px)
were observed in deprenyl-treated rats (Carrillo et
al. 1991,1992; Ki tani et al. 1992). We have not found
a statistically significant increase of CuZn SOD and Mn
SOD activities in the striatum of rats treated with de-
prenyl. The insignificant increase may be ascribed to
the dose of deprenyl applied in our study and according
to the postulated mechanism of its action through trop-
hic factors, to time of application. As acute deprenyl
administration (10 mg/kg s.c.), which inhibits complete-
ly MAO B activity, and 50% of MAO A activity (W a 1-
de ine i r et al. 1981), does not increase extracellular
DAlevel and its content in the brain regions (Azz aro
eta!' 1985;Kato etal.1986;Butcher etal.1990),our
results may be interpreted as a support for the influence
of deprenyl on antioxidant enzyme activities through
the interactions with trophic factors. It has recently
been shown that L-deprenyl increases the survival of
substantia nigra neurons even when the drug is given
days after MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahy-
dropyridine) treatment (T a t ton and G r e e n woo d
1991). L-deprenyl can also retard the degeneration of
cholinergic facial neurons in the rat after axotomy (S a-
10 and Ta t ton 1992). In addition to our results, these
findings suggest a neuroprotective mechanism that can
be related to the stimulation of neurotrophic factors or
regenerative processes. L-deprenyl has been shown in
various experimental studies to exert many effects be-
sides MAO-B inhibition (Lange et al. 1994). Addi-
tional treatment with reserpine induced decreased Mn
SOD (p<0.05) and increased CAT (p<0.05) activities
in the striatum, indicating that this alkaloid acts chang-
ing catecholamine metabolism.
Reserpine influences antioxidant enzyme activi-
ties mainly through the mechanism based on the chan-
ges in catecholamine metabolism (increased extracellu-
lar catabolism and intracellular synthesis). Following
the injection of a large reserpine dose, noradrenaline
from the interscapular brown adipose tissue (IBAT)
practically disappears both in the morning and in the
evening experiments, thus indicating that this reserpine
dose completely depletes noradrenaline (NA) content
from the IBAT (Duv i d ov i c and Pe t r o v i c 1981).
This interpretation is further supported by our
results showing that deprcnyl expressed no effect on
GSH-Px, GR and GST activities in all brain regions
studied, while reserpine induced a significant decrease
of GSH-Px activity in the hypothalamus with thalamus
(p<0.05) in comparison with control animals.
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E<I>EKTI1 ,ll;EITPEHI1JIA, PE3EPITl1HA I1lhl1XOBE KOMEI1HAUI1JE HA AKTI1BHOCT
AHTI10KCl1,ll;ATI1BHl1X EH3l1MA Y M03ry IlAI..l:OBA
11BAHA EO:IJG1li\ AJIEKCAH):(PA HMKOJIMli\ 30PMIJA c. CAWIMli" q. ):(. MMJbEBMli2,
M. E. CITACMli1 nB.M.ITETPOBMli1
IHHciiiuwyiii sa inionoupca uciiipaxcueatea "Cuuuiqa Ciiiauxoeuh", Ooeneu« sa rPU3uo/loiujy,
2Cuequja/lHa iicuxujaiiipujcxa 60/lHuqa ''Jl:p JIa3a Jlasapeeuh", 11000 Eeorpan, JyrOCJIaBHja
AKTHBHOCT aHTHOKClmaTHBHHX eH3HMa: cynepoxcan
,lUicM)'Ta3e (CuZn SOD H Mn SOD), KaTaJIa3e (CAT),
rrryraraon nepoxcanaae (GSH-Px), rnyraTHOH-C-TPaHc-
cpepase (GST) H rnyraraoa penyxrase (GR) y cTPHjaTYMY,
XHIIoKaMIIYcy, XHrrOTaJIaMYcy ca TaJIaMYcoM, xao H oCTaTKY
MOJra, npaheaa je y excnepaaearaaa cyfixporrasnor
rperapaaa nanosa L-.uerrpeHHJIOM, aKYTHor pe3epIIHHoM
H y KOM6HHaIIHjH 06a. Hama pe3yJITaTH noxasyjy na
pe3epIIHH (p<O.02), xao H KOM6HHaIIHja nenpeaana H
pe3epIIHHa (p<O.Ol) nosone no CMaH.eH.a aKTHBHOCTH
CAT y ocrarxy M03ra H aKTHBHOCTH GSH-Px(p<O.05) y
XHIIOTaJIaMYcy ca TaJIaMYcoM. )l;errpeHHJI He H3a3HBa
snaaajne nposreae eH3HMCKe aKTHBHOCTH y HCIIHTHBaHHM
perHOHHMa M03ra. Y excnepasreirrannoj rpYIIH rperapanoj
nenpeaanoa, rra pe3epIIHHOM ,n:OJIa3H no saasajaor- CMaH.e-
H.a aKTHBHOCTH CuZn SOD (p<O.005) xanoxaanyca,
aKTHBHOCTH Mn SOD cTPHjaTYMa (p<O.D5) H noseha,a
aKTHBHOCTH CuZn SOD (p<O.01) ocrarxa M03ra. OBH
pe3yJITaTH yxasyjy na HCl\pIIJI,eH.e rryJIa KaTeXOJIaMHHa
(ycnen 'rpersraaa pe3epIIHHoM) HMa ,lUipeKTaH yranaj aa
aKTHBHOCT aHTHOKClmaTHBHHX eH3HMa, .uOK cy aa ecpex're
nenpeaana saasajae HHTepaKIIHje ca HeKHM Tpoq)H~HM
¢aKTopHMa. .
